

Package ‘midas2’

October 13, 2022

Type Package

Title Bayesian Drug-Combination Platform Design(MIDAS-2)

Version 0.1.0

Author Su Liwen

Maintainer Su Liwen <cpusullivan@163.com>

Description Implementation of Bayesian drug-combination platform design. More and more immunology drug combinations make the traditional two-arm phase II trials inefficient, which stimulate the emerge of platform trials. In the case of multiple trial objectives such as candidates screening and subgroup analysis, we propose an information borrowing drug-combination Bayesian design for platform trials with subgroup exploration. MIDAS-2 consists of one control arm and several experimental agents. We use Bayesian spike and slab prior to identify factors that should be included in regression model and borrow information between combinations in the existence of subgroup interaction. Promising drug combinations are allowed to graduated early to move to next stage and new combination strategies can be added accordingly. Catch-up rule, curtail rule and early stopping rules are also applied to accelerate the trial process.

License GPL-3

Encoding UTF-8

Imports MCMCpack,coda,R2jags

RoxygenNote 7.1.2

NeedsCompilation no

Repository CRAN

Date/Publication 2021-12-16 10:50:02 UTC

R topics documented:

hc_platform 2

Index 4

Description

Implementation of Bayesian drug-combination platform design. More and more immuno-oncology drug combinations make the traditional two-arm phase II trials inefficient, which stimulate the emerge of platform trials. In the case of multiple trial objectives such as candidates screening and subgroup analysis, we propose an information borrowing drug-combination Bayesian design for platform trials with subgroup exploration. MIDAS-2 consists of one control arm and several experimental agents. We use Bayesian spike and slab prior to identify factors that should be included in regression model and borrow information between combinations in the existence of subgroup interaction. Promising drug combinations are allowed to graduated early to move to next stage and new combination strategies can be added accordingly. Catch-up rule, curtail rule and early stopping rules are also applied to accelerate the trial process.

Usage

```
hc_platform(seed, p, p_tox)
```

Arguments

seed	set a random seed to maintain the repeatability of the simulation results.
p	a matrix indicating the efficacy. Row number represents the number of candidate drugs.
p_tox	a vector indicating the toxicity.

Value

term.tox the indicator of whether early stopping for toxicity
 term.fut the indicator of whether early stopping for futility
 term.eff the indicator of whether early stopping for efficacy
 final.eff a vector of final decision, either efficacy or inefficacy
 post.subg subgroup analysis for treatments
 post.sign signature analysis for treatments
 post.spike posterior estimation for spike parameters
 best selection of best treatment for each subgroup

Examples

```
# Example 1
p0 <- c( 0.1, 0.1, 0.1, 0.1)
p1 <- c( 0.1, 0.1, 0.1, 0.1)
```

```
p <- rbind(p0, p1)
p_tox <- c(0.1,0.4)

# consider 1 candidate drugs with 4 subgroups
result <- hc_platform(seed=20,p,p_tox)
result

# Example 2
p0 <- c( 0.1, 0.1, 0.1, 0.1)
p1 <- c( 0.1, 0.1, 0.1, 0.1)
p2 <- c( 0.1, 0.1, 0.1, 0.1)
p3 <- c( 0.1, 0.1, 0.1, 0.1)
p4 <- c( 0.1, 0.1, 0.1, 0.1)
p5 <- c( 0.1, 0.1, 0.1, 0.1)
p6 <- c( 0.1, 0.1, 0.1, 0.1)
p7 <- c( 0.1, 0.1, 0.1, 0.1)

p <- rbind(p0, p1, p2, p3, p4, p5, p6, p7)
p_tox <- c(0.1,0.4,0.1,0.2,0.15,0.1,0.1,0.1)

# consider 7 candidate drugs with 4 subgroups
result <- hc_platform(seed=12,p,p_tox)
result
```

Index

hc_platform, [2](#)